Hong, D., Clarke, J., Johanns, T., Kebriaei, P., Heymach, J., Galal, A., Saibil, S., Sacher, A., Brophy, F., Betts, G., Bath, N., William, S., Tipping, A., Tucci, J., Luke, R., Trivedi, T., Lin, Q., Navenot, J., Fracasso, P., Miller, K., Norry, E., Dudley, M., & Butler, M. (n.d.). 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. Journal for immunotherapy of cancer, 8, A231. http://access.bl.uk/ark:/81055/vdc_100144713039.0x000004